We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Albemarle (ALB - Free Report) closed the most recent trading day at $173.03, moving -2.84% from the previous trading session. This move lagged the S&P 500's daily gain of 0.44%. Elsewhere, the Dow saw an upswing of 0.36%, while the tech-heavy Nasdaq appreciated by 0.54%.
Shares of the specialty chemicals company witnessed a gain of 9.74% over the previous month, beating the performance of the Basic Materials sector with its loss of 5.22%, and the S&P 500's loss of 3.31%.
The investment community will be paying close attention to the earnings performance of Albemarle in its upcoming release. The company is expected to report EPS of $0.78, up 533.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.28 billion, up 18.91% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.15 per share and a revenue of $5.58 billion, indicating changes of +1131.65% and +8.48%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Albemarle. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.51% higher. Albemarle currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 21.85. This represents a premium compared to its industry average Forward P/E of 18.86.
We can additionally observe that ALB currently boasts a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Chemical - Diversified industry had an average PEG ratio of 1.63.
The Chemical - Diversified industry is part of the Basic Materials sector. With its current Zacks Industry Rank of 227, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Stock Sinks As Market Gains: What You Should Know
Albemarle (ALB - Free Report) closed the most recent trading day at $173.03, moving -2.84% from the previous trading session. This move lagged the S&P 500's daily gain of 0.44%. Elsewhere, the Dow saw an upswing of 0.36%, while the tech-heavy Nasdaq appreciated by 0.54%.
Shares of the specialty chemicals company witnessed a gain of 9.74% over the previous month, beating the performance of the Basic Materials sector with its loss of 5.22%, and the S&P 500's loss of 3.31%.
The investment community will be paying close attention to the earnings performance of Albemarle in its upcoming release. The company is expected to report EPS of $0.78, up 533.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.28 billion, up 18.91% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.15 per share and a revenue of $5.58 billion, indicating changes of +1131.65% and +8.48%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Albemarle. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.51% higher. Albemarle currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 21.85. This represents a premium compared to its industry average Forward P/E of 18.86.
We can additionally observe that ALB currently boasts a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Chemical - Diversified industry had an average PEG ratio of 1.63.
The Chemical - Diversified industry is part of the Basic Materials sector. With its current Zacks Industry Rank of 227, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.